[Skip to Content]
[Skip to Content Landing]

How Scientists Used CRISPR to Edit Human DNA In Vivo

CRISPR-Cas9 technology is used to edit DNA to correct genetic abnormalities, but until now has required that tissue samples be removed for gene editing outside the body. In March 2020 researchers announced a test of the first in vivo CRISPR-Cas9 treatment for Leber congenital amaurosis (LCA) type 10, a condition that causes severe, early-onset vision loss. This video explains the principles of DNA editing with CRISPR-Cas9 and the rationale for its use and testing as a therapy for LCA10 in the BRILLIANCE clinical trial. Click the related article link to read a review of the range of clinical trials testing CRISPR as a treatment for human disease in 2020.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close